

Recommended Regimens for Hepatitis C Treatment

Based on Cirrhosis/Post-Liver Transplant/Renal Impairment Status

Patient Genotype and Treatment Experience	Post-Liver Transplant, Non-Cirrhotic or Compensated Cirrhotic	Post-Liver Transplant, Decompensated Cirrhotic	Renally Impaired (CrCl < 30ml/min)
1	Naïve	<ul style="list-style-type: none"> Mavyret x 12 weeks Epclusa X 12 weeks Harvoni X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Harvoni + RBV X 12 weeks
	Non-DAA Experienced	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 12 weeks Harvoni x 12 weeks 	<ul style="list-style-type: none"> Epclusa+ RBV x 24 weeks Harvoni + RBV x 24 weeks
2	Naïve	<ul style="list-style-type: none"> Mavyret X 12 weeks Epclusa X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV 12 weeks
	Non-DAA Experienced	<ul style="list-style-type: none"> Mavyret x 12 weeks Epclusa x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
3	Naïve	<ul style="list-style-type: none"> Epclusa X 12 weeks Mavyret X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV 12 weeks
	Non-DAA Experienced	<ul style="list-style-type: none"> Epclusa X 12 weeks Mavyret X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV 24 weeks
4	Naïve	<ul style="list-style-type: none"> Mavyret X 12 weeks Epclusa X 12 weeks Harvoni x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Harvoni + RBV x 12 weeks
	Non-DAA Experienced	<ul style="list-style-type: none"> Mavyret X 12 weeks Epclusa X 12 weeks Harvoni x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV 24 weeks
5/6	Naïve	<ul style="list-style-type: none"> Epclusa X 12 weeks Mavyret X 12 weeks Harvoni X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV 12 weeks Harvoni + RBV 12 weeks
	Non-DAA Experienced	<ul style="list-style-type: none"> Epclusa X 12 weeks Mavyret X 12 weeks Harvoni X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
1-6	DAA Experienced	<ul style="list-style-type: none"> Vosevi x 12 weeks 	

HCV Treatment Overview

Information provided based on FDA-approved labeling. Practice guidelines may include additional treatment options. See prescribing information for details.

FDA-Labeled HCV Treatments					
Drug	Genotypes	HIV Co-Infection	Liver Transplant	Decompensated Cirrhosis	Treatment Duration
Epclusa	1, 2, 3, 4, 5, 6	✓	✓	✓	12 or 24 weeks
Harvoni	1, 4, 5, 6	✓	✓	✓	8, 12, or 24 weeks
Mavyret	1, 2, 3, 4, 5, 6	✓	✓		8, 12, 16, or 24 weeks
Vosevi	1, 2, 3, 4, 5, 6	✓	✓		12 or 24 weeks
Zepatier	1, 4 must test for NS5A resistance	✓			8 or 12 weeks

Special Population	Recommended Regimen(s)
HIV Co-Infection	Epclusa, Harvoni, Mavyret, Vosevi, Zepatier (follow dose recommendations on previous pages. Check for drug interaction between HIV medications and DAAs)
Pediatric Patients	Epclusa – 3 years and older, pediatric dosing may apply based on weight Harvoni – 3 years and older, pediatric dosing may apply based on weight Mavyret – 3 years and older, pediatric dosing may apply based on weight Zepatier – 12 years of age or older, or weighing ≥ 30kg

Transforming Lives with Compassionate Care

VISIT US ONLINE
AcariaHealth.com |  @AcariaHealth

[AcariaHealth.com](https://www.AcariaHealth.com)

© 2024 AcariaHealth. All rights reserved. Information for Prescribers. 240410

Phone: 800.511.5144 | Fax: 877.541.1503



Recommended Regimens for
Hepatitis C Treatment
(AASLD/IDSA/FDA Guidelines)

AcariaHealthTM
Specialty Pharmacy

Recommended Regimens for Hepatitis C Treatment

Based on Cirrhosis Status

Patient Genotype and Treatment Experience	Recommended Regimen(s) Based on Cirrhosis Status			
	Non-Cirrhotic	Compensated Cirrhotic	Decompensated Cirrhotic	
1A	Naïve	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 8 weeks Harvoni x 12 weeks Harvoni x 8 weeks (HIV un-infected and HCV RNA < 6 million) 	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 8 weeks Harvoni x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks Harvoni + RBV x 12 weeks Harvoni x 24 weeks
	Sofosbuvir-based treatment failures	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Elbasvir/grazoprevir treatment failures	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Glecaprevir/pibrentasvir treatment failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi + RBV x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Multiple DAA regimen failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Naïve	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks Harvoni x 8 weeks (HIV un-infected and HCV RNA < 6 million) Harvoni x 12 weeks Zepatier x 12 weeks² 	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks Harvoni x 12 weeks Zepatier x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks Harvoni + RBV x 12 weeks Harvoni x 24 weeks
1B	Sofosbuvir-based treatment failures	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Elbasvir/grazoprevir treatment failures	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Glecaprevir/pibrentasvir treatment failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi+ RBV x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Multiple DAA regimen failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Naïve	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks Harvoni x 8 weeks (HIV un-infected and HCV RNA < 6 million) Harvoni x 12 weeks Zepatier x 12 weeks² 	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks Harvoni x 12 weeks Zepatier x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks Harvoni + RBV x 12 weeks Harvoni x 24 weeks

Patient Genotype and Treatment Experience	Recommended Regimen(s) Based on Cirrhosis Status			
	Non-Cirrhotic	Compensated Cirrhotic	Decompensated Cirrhotic	
2	Naïve	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks 	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 8 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks
	Sofosbuvir-based treatment failures	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
	Elbasvir/grazoprevir treatment failures	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
	Glecaprevir/pibrentasvir treatment failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi + RBV x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
	Multiple DAA regimen failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
	Naïve	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 8 weeks 	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks (Y93H-) Epclusa + RBV x 12 weeks (Y93H+) Vosevi x 12 weeks (with Y93H+) 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks
3	Sofosbuvir-based treatment failures	<ul style="list-style-type: none"> Vosevi X 12 weeks 	<ul style="list-style-type: none"> Vosevi X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
	Elbasvir/grazoprevir treatment failures	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Vosevi X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
	Glecaprevir/pibrentasvir treatment failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi + RBV x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV X 24 weeks
	Multiple DAA regimen failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 24 weeks Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks
	Naïve	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 8 weeks 	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks (Y93H-) Epclusa + RBV x 12 weeks (Y93H+) Vosevi x 12 weeks (with Y93H+) 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks

Patient Genotype and Treatment Experience	Recommended Regimen(s) Based on Cirrhosis Status			
	Non-Cirrhotic	Compensated Cirrhotic	Decompensated Cirrhotic	
4	Naïve	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks Harvoni x 8 weeks (HIV uninfected and HCV RNA < 6 million, absence of GT4r) Harvoni x 12 weeks Zepatier x 12 weeks 	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 8 weeks Harvoni x 12 weeks Zepatier x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks Harvoni + RBV x 12 weeks Harvoni x 24 weeks
	Sofosbuvir-based treatment failures	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Elbasvir/grazoprevir treatment failures	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Glecaprevir/pibrentasvir treatment failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi + RBV x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Multiple DAA regimen failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Naïve	<ul style="list-style-type: none"> Epclusa x 12 weeks Mavyret x 8 weeks Harvoni x 12 weeks (not for GT6e) 	<ul style="list-style-type: none"> Mavyret x 8 weeks Epclusa x 12 weeks Harvoni x 12 weeks (not for GT6e) 	<ul style="list-style-type: none"> Epclusa + RBV x 12 weeks Epclusa x 24 weeks Harvoni + RBV x 12 weeks Harvoni x 24 weeks
5/6	Sofosbuvir-based treatment failures	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Elbasvir/grazoprevir treatment failures	<ul style="list-style-type: none"> Vosevi x 12 weeks 	<ul style="list-style-type: none"> Vosevi X 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Glecaprevir/pibrentasvir treatment failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi x 12 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks Vosevi + RBV x 12 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks
	Multiple DAA regimen failures	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Mavyret + Sovaldi + RBV x 16 weeks¹ Vosevi + RBV x 24 weeks 	<ul style="list-style-type: none"> Epclusa + RBV x 24 weeks Harvoni + RBV x 24 weeks

¹ Extend duration Mavyret + Sovaldi + RBV x 24 weeks in cases after Mavyret + Sovaldi failure

² May use Zepatier x 8 weeks for patients with mild fibrosis without cirrhosis